.jpeg)
2026-07-23 06:02:51
Orforglipron (brand name Foundayo) is the first approved oral small-molecule non-peptide GLP-1 receptor agonist for long-term weight management in adults with obesity or overweight, taken once daily without food or water restrictions.
2026-06-25 06:42:02
Learn the principles of discontinuing mirogabalin for neuropathic pain. This guide covers physical dependence, stepwise tapering, withdrawal symptom management, and special population adjustments.
2026-06-16 04:16:36
This article illustrates the action pathways, eligible patient groups and medication characteristics of pemafibrate in triglyceride reduction, and analyzes its role and benefits in the treatment of lipid metabolic disorders.
2026-05-28 02:09:41
covering pre-test preparation, midnight dosing, blood sampling, and result interpretation.
2026-05-20 02:14:35
Discover how Trelagliptin offers a breakthrough in Type 2 Diabetes management with its once-weekly dosing, superior adherence, stable glycemic control, and long-term safety profile.
2026-04-29 06:37:21
Loargys(Pegzilarginase-nbln) is a pegylated arginase replacement therapy for the long-term management of arginase 1 deficiency. This guide provides detailed information on pre-treatment preparation, dose adjustment and monitoring requirements during treatment, and standardized home subcutaneous injection procedures to help patients and healthcare providers use this medication safely and effectively.
2026-04-03 06:19:35
Cabergoline is a highly selective long-acting dopamine D2 receptor agonist, the first-line treatment for hyperprolactinemia (HPRL), pituitary prolactinoma, and physiological lactation suppression. Its core clinical dosing strategy follows low-dose initiation with gradual individualized titration. This article details its full clinical specifications, including dosing regimens, dose adjustment principles, indication-specific treatment duration, and post-discontinuation monitoring.
